Pulocimab

DB18938InvestigationalProtein Based Therapies

Pulocimab is under investigation in clinical trial NCT06341335 (A Study of Ak104/placebo Plus Ak109/placebo and Paclitaxel in Gastric or Gastroesophageal Junction Adenocarcinoma).

Mechanism: Pharmacologically active on Vascular endothelial growth factor receptor 2
Curator reviewed
Also known as: Immunoglobulin g1, anti-(human vascular endothelial growth factor receptor 2) (human monoclonal ak109 .gamma.1-chain), disulfide with human monoclonal ak109 .kappa.-chain, dimer
Code names: AK-109

Resolves to

Compound

UNIIFDL8DA4XV4CAS2428381-49-9

Targets

P35968KDR

What you can answer from here — as of July 09, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

4Clinical trialsPhase, status and sponsor resolved per trial

1+ReferenceStructured and connected to the statements they support

Which drugs share a target with Pulocimab, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account